A patient received an initial Invega LAI (paliperidone palmitate) 234 mg injection and a second 234 mg injection six days later; she now has persistent internal stimulation (akathisia). How should the dosing be corrected and the akathisia be managed?

Incorrect Dosing Schedule and Akathisia Management

The patient received an incorrect Invega LAI initiation schedule—the second 234 mg dose should have been given on day 8 (±4 days), not day 6, and the persistent internal stimulation (akathisia) requires immediate intervention with dose reduction or adjunctive medication.

Critical Dosing Error

The FDA-approved initiation regimen for Invega LAI (paliperidone palmitate 1-month) is 234 mg on day 1 followed by 156 mg on day 8 (±4 days), both administered in the deltoid muscle 1. Your patient received:

• Day 1: 234 mg ✓ (correct)
• Day 6: 234 mg ✗ (incorrect—should be 156 mg on day 8)

This represents two significant errors:

1. Timing: Day 6 falls outside the acceptable window (days 4-12) 2
2. Dose: 234 mg instead of the required 156 mg second dose

Research confirms that while the day 8 dose can be given between days 4-12 without significant pharmacokinetic impact 2, the dose itself must be 156 mg, not 234 mg 3. The patient essentially received a loading dose overdose.

Managing the Akathisia

Akathisia is a common and distressing extrapyramidal side effect that frequently leads to medication non-adherence and must be treated aggressively 4.

Immediate Treatment Options (Choose One):

First-line approach 4, 5:

• Beta-blocker: Propranolol 10-30 mg TID (most evidence-based for akathisia)
• Benzodiazepine: Lorazepam 0.5-1 mg BID-TID 4, 6

Alternative if above ineffective 5:

• Consider switching to a different antipsychotic with lower EPS risk once the long-acting formulation clears

Critical Pitfall to Avoid:

Do NOT add anticholinergics (benztropine, trihexyphenidyl) as first-line—they are ineffective for akathisia and may worsen symptoms 4, 5. Anticholinergics work for dystonia and parkinsonism, but akathisia requires beta-blockers or benzodiazepines.

Pharmacokinetic Considerations

The long-acting formulation creates a unique challenge: paliperidone levels will remain elevated for weeks to months 3, 7. After the 1-month formulation:

• Therapeutic levels are maintained for 4-6 weeks
• Complete clearance takes significantly longer
• The overdose (234 mg × 2 instead of 234 mg + 156 mg) will prolong elevated plasma concentrations

You cannot simply "stop" the medication—it will continue releasing for weeks 8, 9.

Monitoring Requirements

Given the dosing error and akathisia:

1. Assess akathisia severity using a structured scale (Barnes Akathisia Rating Scale)
2. Monitor for other EPS: dystonia, parkinsonism, which may emerge 4, 10
3. Check for NMS warning signs: fever, rigidity, altered mental status, autonomic instability 10, 9
4. Baseline and ongoing AIMS (Abnormal Involuntary Movement Scale) every 3-6 months to detect tardive dyskinesia early 4, 11, 12

Future Dosing Correction

Do NOT give another injection until the appropriate monthly interval (approximately 4 weeks from the day 6 injection). When resuming:

• Use the recommended maintenance dose of 117 mg monthly (not 234 mg) 1
• Can be given deltoid or gluteal
• Maintain ±7 day flexibility for monthly doses 3

Documentation and Risk Mitigation

Document this medication error formally. The patient received approximately 1.5× the intended loading dose, which increases risk for:

• Prolonged EPS (including the current akathisia) 13, 7
• Tardive dyskinesia with extended exposure 11, 12
• Metabolic effects
• Hyperprolactinemia

Obtain informed consent for continuing LAI therapy given the error and current side effects, discussing alternatives including oral antipsychotics or different LAI formulations with lower EPS profiles 5.